NMDA-antagonisten bij de behandeling van katatonie: amantadine, memantine en ketamine
Scott R. Beach
June 30, 2025 DOI: 10.64239/pi-nl-vl9408 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review |
|---|---|
| Interventions | Amantadine Memantine Ketamine ECT |
| Topics | Esketamine Ketamine |
| Key findings | Argues that NMDA antagonists such as amantadine and memantine are third-line treatments for catatonia, after benzodiazepines and ECT, and are most often used as augmentation of benzodiazepines. Although ketamine has shown a 91% response rate in some cases, it is not recommended because of unpredictability and the potential to worsen symptoms. |
Abstract
NMDA-antagonisten zoals amantadine en memantine worden beschouwd als derdelijnsbehandelingen voor katatonie, na benzodiazepinen en ECT. NMDA-antagonisten kunnen als monotherapie worden ingezet bij katatonie, maar worden het meest gebruikt als augmentatie van benzodiazepinen. Ondanks een responspercentage van 91% in sommige gevallen, wordt ketamine niet aanbevolen bij katatonie vanwege de onvoorspelbaarheid en het potentieel om symptomen te verergeren.
Comparable studies
Other narrative reviews on ketamine, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms | 2018 | Review | |
| Mechanisms of Ketamine Action as an Antidepressant | 2018 | Review | |
| Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation Adults with treatment-resistant depression | 2021 | Review | |
| Ketamine Pharmacology: An Update (Pharmacodynamics and Molecular Aspects, Recent Findings) | 2013 | Review | |
| A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders | 2017 | Review and consensus statement |